Effects of different meal compositions and fasted state on the oral bioavailability of etravirine

Pharmacotherapy

Volumn 28, Issue 10, 2008, Pages 1215-1222

  Schöller Gyüre, Monika ^a   Boffito, Marta ^b   Pozniak, Anton L ^b   Leemans, Ruud ^c   Kakuda, Thomas N ^d   Woodfall, Brian ^a   Vyncke, Veerle ^a   Peeters, Monika ^a   Vandermeulen, Kati ^a   Hoetelmans, Richard M W ^a  

^a TIBOTEC BVBA   (Belgium)

^b CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d Tibotec Inc   (United States)

Author keywords

Etravirine; Food effect; Nonnucleoside reverse transcriptase inhibitor; Pharmacokinetics; TMC125

Indexed keywords

ETRAVIRINE; INTELENCE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG BIOAVAILABILITY; DRUG EXPOSURE; DRUG FORMULATION; DRUG PENETRATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; FOOD COMPOSITION; FOOD DRUG INTERACTION; HEADACHE; HIGH FIBER DIET; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID DIET; MALE; MAXIMUM PLASMA CONCENTRATION; MEAL; NORMAL HUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; TABLET;

ADMINISTRATION, ORAL; ADULT; ANTI-HIV AGENTS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; FASTING; FOOD; FOOD-DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; PYRIDAZINES; REVERSE TRANSCRIPTASE INHIBITORS; YOUNG ADULT;

EID: 54749118543     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.10.1215     Document Type: Article

References (30)

1. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005;352:48-62.
2. Andries K, Azijn H, Thielemans T, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004;48:4680-6.
3. Vingerhoets J, Azijn H, Fransen E, et al. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol 2005;79:12773-82.
4. Gazzard BG, Pozniak AL, Rosenbaum W, et al. An open-label assessment of TMC125 - a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS 2003;17:F49-54.
5. Cohen C, Steinhart CR, Ward DJ, et al. Efficacy and safety results at 48 weeks with the novel NNRT1, TMC125, and impact of baseline resistance on the virologic response in study TMC125-C223. Presented at the 16th international AIDS conference, Toronto, Canada, August 13-18, 2006.
6. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:29-38.
7. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:39-48.
8. Haubrich R, Cahn P, Grinsztejn B, et al. DUET-1: week 48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 versus placebo in 612 treatment-experienced HIV-1 infected patients. Presented at the 15th conference on retroviruses and opportunistic infections, Boston, MA, February 3-6, 2008.
9. Johnson M, Campbell T, Clotet B, et al. DUET-2: week 48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 versus placebo in 591 treatment-experienced HIV-1 infected patients. Presented at the 15th conference on retroviruses and opportunistic infections, Boston, MA, February 3-6, 2008.
10. Kakuda TN, Schöller-Gyüre M, Workman C, et al. Single and multiple dose pharmacokinetics of etravirine administered as two different formulations in HIV-1 infected patients. Antiviral Ther, in press.
11. Piscitelli S, Bade P, De Dier K, Van't Klooster G, Graham N. Pharmacokinetics of TMC125 in HIV-infected patients and healthy volunteers. Presented at the third international workshop on clinical pharmacology of HIV therapy, Washington, DC, April 11-13, 2002.
12. Tibotec Pharmaceuticals, Ltd. Data on file. Cork, Ireland; 2005.
13. Regulatory Compliance Center. Tables for grading severity of adult adverse experiences; August 1992. Available from http://rcc.tech-res-intl.com/ tox_tables.htm. Accessed January 7, 2008.
14. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
15. Schöller-Gyüre M, Kakuda TN, Sekar V, et al. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antiviral Ther 2007;12:789-96.
16. Levy RH, Pitlick WH, Troupin AS, Green JR, Neal JM. Pharmacokinetics of carbamazepine in normal man. Clin Pharmacol Ther 1975;17(6):657-68.
17. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2003;57:218-22.
18. Humberstone AJ, Porter CJ, Charman WN. A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine. J Pharm Sci 1996;85:525-9.
19. Cai X, Grant DJ, Wiedmann TS. Analysis of the solubilization of steroids by bile salt micelles. J Pharm Sci 1997;86:372-7.
20. Perry CM, Benfield P. Nelfinavir. Drugs 1997;54:81-7.
21. Charman W, Porter CJ, Mithani S, Dressman JB. Physicochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J Pharm Sci 1997;86:269-82.
22. Fleisher D, Li C, Zhou Y, Pao L, Karim A. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clin Pharmacokinet 1999;36:233-54.
23. Welling PG. Effects of food on drug absorption. Annu Rev Nutr 1996;16:383-415.
24. Mojaverian P, Ferguson RK, Vlasses PH, et al. Estimation of gastric residence time of the Heidelberg capsule in humans: effects of varying food composition. Gastroenterology 1985;89:392-7.
25. Schöller-Gyüre M, Kakuda T, De Smedt G, et al. A pharmacokinetic study of etravirine (TMC125) coadministered with ranitidine and omeprazole in HIV-negative volunteers. Br J Clin Pharmacol, in press.
26. Reppas C, Meyer JH, Sirois PJ, Dressman JB. Effect of hydroxypropylmethylcellulose on gastrointestinal transit and luminal viscosity in dogs. Gastroenterology 1991;100:1217-23.
27. Spiller RC. Pharmacology of dietary fibre. Pharmacol Ther 1994;62:407-27.
28. Lutz M, Espinoza J, Arancibia A, Araya M, Pacheco I, Brunser O. Effect of structured dietary fiber on bioavailability of amoxicillin. Clin Pharmacol Ther 1987;42:220-4.
29. Gin H, Orgerie MB, Aubertin J. The influence of guar gum on absorption of metformin from the gut in healthy volunteers. Horm Metab Res 1989;21:81-3.
30. Kakuda TN, Wade JR, Snoek E, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of the non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC125 in treatment-experienced HIV-1 infected patients: pooled 24-week results of DUET-1 and DUET-2. Presented at the 15th conference on retroviruses and opportunistic infections, Boston, MA, February 3-6, 2008.